#USA #UroMems #Grenoble #UroActive #Dan Rose

UroMems Welcomes Dan Rose as New Board Chairman

UroMems, a pioneering company in the medical technology field, has officially appointed Dan Rose as the new chairman of its board of directors. This announcement comes at a pivotal moment for the company as it gears up to conduct significant clinical trials for its innovative product, UroActive, designed to treat stress urinary incontinence (SUI).

Significant Leadership Transition

The announcement was made on January 30, 2025, emphasizing the excitement surrounding the transition. Hamid Lamraoui, co-founder and CEO of UroMems, expressed enthusiasm about the appointment, highlighting Rose's extensive leadership experience in the medical device sector. Lamraoui stated, “Dan's proven track record positions him well as UroMems advances toward our next phase of large-scale clinical trials in the U.S. and Europe.” The need for innovative solutions in treating urinary incontinence has never been more urgent, and Rose's leadership is expected to steer the company towards success.

Dan Rose brings over 25 years of experience in the medical technology field, currently serving as the CEO of Endovascular Engineering, a Silicon Valley-based company focused on treating venous thromboembolism. His previous roles include executive positions at LimFlow S.A., Direct Flow Medical, Sequana Medical AG, and Medtronic. Rose's broad experience in leading startups as well as established organizations is poised to benefit UroMems immensely during its clinical trial and commercial launch phases.

Tackling a Major Health Challenge

Stress urinary incontinence is a widespread issue that affects approximately 40 million Americans and 90 million Europeans. Those living with this condition often endure a diminished quality of life. UroActive, the implantable device engineered by UroMems, aims to address the deficiencies of current treatments by providing a more effective and patient-centered solution for both men and women.

Dan Rose expressed gratitude for the opportunity to lead UroMems during this crucial time, emphasizing his commitment to enhancing the quality of life for millions of patients suffering from SUI. “I am impressed by the momentum that UroMems has achieved so far and I look forward to helping bring their innovative, patient-focused technology to the next phase,” said Rose.

Innovative Product Development

UroActive stands out as the world's first intelligent automated artificial urinary sphincter. The innovative technology is backed by over 150 granted patents and delivers on optimizing both safety and performance, along with enhanced patient experience and surgical convenience. However, it's important to note that UroActive has yet to receive marketing authorization from the FDA and is not available for sale in the U.S. or the EU.

UroMems has made significant strides in research and development recently, including securing $47 million in funding, following successful early multicenter clinical studies. The results have propelled UroMems into the spotlight, demonstrating not only the demand for advancements in urinary incontinence solutions but also the company's capability to meet that demand.

Future Outlook

As UroMems moves into this new chapter of pivotal clinical trials and impending market launch, the company stands prepared to make a substantial impact in the medical community. With Dan Rose at the helm as chairman of the board, UroMems is positioned to enhance the lives of many battling urinary incontinence, paving the way for innovative medical solutions to address this pervasive health issue. To find out more about UroMems and their groundbreaking work, visit their website at www.uromems.com.